Table 4 Vital signs and most frequent treatment adverse events
GXST (n = 143) | Placebo (n = 144) | Total (n = 287) | |
|---|---|---|---|
Vital signs | |||
HR (beats/min) | 71.2 ± 9.3 | 69.6 ± 8.9 | 70.2 ± 9.0 |
SBP (mmHg) | 127.5 ± 9.3 | 127.5 ± 7.9 | 127.5 ± 8.5 |
DBP (mmHg) | 80.9 ± 6.3 | 80.7 ± 6.5 | 80.9 ± 6.3 |
Adverse events | |||
Fever | 0 (0.0%) | 1 (0.7%) | 1 (0.3%) |
Hypertension | 0 (0.0%) | 1 (0.7%) | 1 (0.3%) |
Palpitation | 0 (0.0%) | 1 (0.7%) | 1 (0.3%) |
Urinary tract infection | 1 (0.7%) | 0 (0.0%) | 1 (0.3%) |
Upper respiratory tract infection | 1 (0.7%) | 0 (0.0%) | 1 (0.3%) |
Gastrointestinal discomfort | 5 (3.5%) | 0 (0.0%) | 5 (1.7%) |
Total | 7 (4.9%) | 3 (2.1%) | 10 (3.5%) |